What is the recommended evaluation for a patient with polyostotic fibrous dysplasia?

Evaluation of Polyostotic Fibrous Dysplasia

All patients with suspected polyostotic fibrous dysplasia require a complete skeletal radiographic survey, comprehensive endocrine evaluation, and phosphorus metabolism testing at initial diagnosis, with whole-body imaging (preferably MRI or bone scintigraphy) to map the full extent of disease.

Initial Clinical Assessment

Begin with a thorough history focusing on:

• Bone pain characteristics (location, duration, relationship to activity)
• History of fractures (age at first fracture, frequency, sites)
• Café-au-lait skin lesions
• Signs of endocrinopathy: precocious puberty, hyperthyroidism, growth hormone excess, Cushing syndrome
• Family history (though this is a non-inheritable genetic mutation) 1, 2

Physical examination should specifically assess for:

• Skeletal deformities (shepherd's crook deformity of femur, genu valgum, limb length discrepancy)
• Café-au-lait spots with irregular "coast of Maine" borders
• Signs of endocrine dysfunction
• Facial asymmetry or craniofacial involvement 1, 2

Laboratory Evaluation

Mandatory baseline laboratory tests 3:

• Complete blood count with differential
• Inflammatory markers (ESR, CRP)
• Renal function
• Alkaline phosphatase (often elevated in active disease)
• Calcium, phosphate, 25-hydroxy-vitamin D, parathyroid hormone (critical to exclude other metabolic bone diseases and identify phosphaturia)
• Bone turnover markers (P1NP, CTx) - particularly useful for monitoring disease activity

Endocrine evaluation 4, 5:

• Thyroid function tests
• Growth hormone/IGF-1 levels
• Cortisol levels
• Sex hormones (especially in children with signs of precocious puberty)
• Consider pituitary imaging (CT or MRI) if acromegaly or other pituitary dysfunction suspected

Critical caveat: Phosphaturia is associated with earlier fractures (mean age 5.1 vs 16.6 years) and higher fracture rates (0.35 vs 0.08 fractures/year), making its identification prognostically important 5.

Imaging Evaluation

Initial Radiographic Assessment

Plain radiographs of all symptomatic areas showing 1:

• Ground-glass or hazy appearance of medullary bone
• Cortical thinning with bone expansion
• Shepherd's crook deformity (proximal femur)
• "Rind sign" (thin sclerotic rim)

Whole-Body Imaging for Disease Mapping

Whole-body MRI is preferred for comprehensive skeletal survey 3, 6:

• Maps clinically silent but radiologically active lesions
• Avoids radiation exposure (critical in pediatric patients)
• Provides superior soft tissue detail
• Should include sagittal spinal images

Alternative options when MRI unavailable or contraindicated 3:

• Technetium-99m bone scintigraphy (shows increased uptake in active lesions)
• PET/CT with bone-seeking radiotracer
• Combined SPECT/CT

Important note: FDG-PET/CT may show heterogeneous uptake in fibrous dysplasia lesions corresponding to different metabolic stages of disease. While lesions can be FDG-avid, this does not indicate malignancy but rather disease activity 6.

Advanced Imaging for Specific Indications

CT scanning 7, 6:

• Useful for assessing ground-glass densities
• Better delineates cortical integrity and fracture risk
• Helpful for surgical planning
• Consider for craniofacial involvement

MRI with contrast 6:

• For suspected complications (pathologic fracture, malignant transformation - extremely rare)
• Characterization of symptomatic lesions
• Pre-surgical planning

Biopsy Considerations

Reserve bone biopsy for 3:

• Inconclusive imaging findings
• Suspicion of malignancy (exceedingly rare but documented)
• Atypical presentation requiring histologic confirmation
• First-time diagnosis when imaging is not pathognomonic

Do not perform routine biopsies when clinical and radiographic features are characteristic 3.

Age-Specific Considerations

Pediatric patients (peak fracture risk 6-10 years) 5:

• More aggressive surveillance protocol
• Minimize radiation exposure (prefer MRI over CT)
• Earlier and more frequent endocrine screening
• Phosphaturia screening is critical as it predicts earlier fractures

Adult patients 8, 6:

• Though typically diagnosed in childhood, polyostotic fibrous dysplasia can present in adulthood
• Same comprehensive evaluation required
• Lower fracture risk after first decade but deformities may progress

Follow-Up Evaluation Strategy

Repeat endocrine evaluation at follow-up visits 4:

• Endocrinopathies may develop over time
• Annual screening for patients with McCune-Albright syndrome
• Monitor for development of acromegaly, hyperthyroidism

Serial imaging:

• Plain radiographs to monitor known lesions and detect new fractures
• Repeat whole-body imaging if new symptoms develop
• Alkaline phosphatase levels correlate with disease activity

Common Pitfalls to Avoid

1. Failing to screen for phosphaturia: This is the single most important metabolic predictor of fracture risk and should never be omitted 5
2. Incomplete skeletal survey: Polyostotic disease requires whole-body assessment, not just symptomatic areas
3. Missing endocrinopathies: These develop over time and require ongoing surveillance, not just baseline screening 4
4. Assuming monostotic disease: What appears as a single lesion may be polyostotic on comprehensive imaging
5. Over-reliance on plain radiographs: These miss early or subtle lesions that whole-body MRI or bone scan would detect